Taken together, these results demonstrate that CD146‐targeted NIR PIT using IR700‐YY146 may serve as a promising alternative for treating small melanomas, mainly by producing ROS and singlet oxygen, reducing glucose metabolism, and decreasing the expression level of CD146. Here, MCAM is linked to melanoma.